1. Investigating synergy between WEE1 and PARP inhibitors in BRCA2 mutant and corrected cells. (October 2020) Authors: Smith, H.; Prendergast, L.; Curtin, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS. (23rd June 2022) Authors: Gill, H.; Yacoub, A.; Pettit, K.; Bradley, T.; Gerds, A.; Tatarczuch, M.; Shortt, J.; Curtin, N.; Rossetti, J.; Burbury, K.; Mead, A.; Göthert, J.; Koschmieder, S.; Jones, A.; Peppe, J.; Dias, J.; Natsoulis, G.; McClure, T.; Kleppe, M.; Hong, W.-J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Potential use of the PARP inhibitor rucaparib to enhance cervical cancer treatment. (October 2020) Authors: Saha, S.; Howarth, R.; Pappworth, I.; Marchbank, K.; Curtin, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SP-0517: Increasing the therapeutic index of radiation by combination with rucaparib in cervical cancer. (November 2020) Authors: Saha, S.; Howarth, R.; Dubrovska, A.; Marchbank, K.; Curtin, N. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗